Oliver A. Kent

101 College Street, M5G 1×5
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.

Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 17, 2026

Design of a peripherally biased NPSR1 antagonist for neuropeptide S induced inflammation.

Design of a peripherally biased NPSR1 antagonist for neuropeptide S induced inflammation.

Journal: Bioorganic & medicinal chemistry letters

Published: June 23, 2025

Interactome of FMRP-N-tat therapeutic unveils key interactions for cellular function in Fragile X neurons.

Interactome of FMRP-N-tat therapeutic unveils key interactions for cellular function in Fragile X neurons.

Journal: The Journal of biological chemistry

Published: May 14, 2025

Disruption of Plexin-A1 signaling by FTX-101: mode of action and effect on oligodendrocyte biology.

Disruption of Plexin-A1 signaling by FTX-101: mode of action and effect on oligodendrocyte biology.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 21, 2025

Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.

Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.

Journal: OncoTargets and therapy

Published: September 23, 2024

Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma.

Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma.

Journal: OncoTargets and therapy

Published: June 12, 2022

Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Journal: The Journal of clinical investigation

Published: July 24, 2020

Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes.

Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes.

Journal: Nature communications

Published: March 03, 2020

Increased mutant KRAS gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?

Increased mutant KRAS gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?

Journal: Hepatobiliary surgery and nutrition

Published: December 01, 2018

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge.

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge.

Journal: Journal of visualized experiments : JoVE

Published: July 10, 2018

Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.

Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.

Journal: Small GTPases

Published: June 29, 2017

Divergent Effects of miR-181 Family Members on Myocardial Function Through Protective Cytosolic and Detrimental Mitochondrial microRNA Targets.

Divergent Effects of miR-181 Family Members on Myocardial Function Through Protective Cytosolic and Detrimental Mitochondrial microRNA Targets.

Journal: Journal of the American Heart Association

Published: March 01, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026